Distinct MR Imaging Features of Triple-Negative Breast Cancer with Brain Metastasis

Journal of Neuroimaging

Volumn 25, Issue 3, 2015, Pages 474-481

  Yeh, Ren Hua ^a   Yu, Jyh Cherng ^a   Chu, Chi Hong ^a   Ho, Ching Liang ^a   Kao, Hung Wen ^a   Liao, Guo Shiou ^a   Chen, Ho Wen ^a   Kao, Woei Yau ^a   Yu, Cheng Ping ^a   Chao, Tsu Yi ^b   Dai, Ming Shen ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Brain metastasis; Breast cancer; Necrotic lesion; Triple negative

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GADOBUTROL;

ADULT; AGED; ARTICLE; ATAXIA; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CEREBELLUM; DISEASE ASSOCIATION; DIZZINESS; FEMALE; FRONTAL LOBE; HEADACHE; HEMIPARESIS; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; METASTASIS RESECTION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OVERALL SURVIVAL; PARIETAL LOBE; RETROSPECTIVE STUDY; SURVIVAL TIME; THICKNESS; TRIPLE NEGATIVE BREAST CANCER; VERTIGO; VISUAL DISORDER; BRAIN TUMOR; COMPUTER ASSISTED DIAGNOSIS; MIDDLE AGED; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SECONDARY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84929030395     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/jon.12149     Document Type: Article

References (30)

1. Arslan UY, Oksuzoglu B, Aksoy S, et al. Breast cancer subtypes and outcomes of central nervous system metastases. Breast 2011;20:562-567.
2. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004;22:2865-2872.
3. Weil RJ, Palmieri DC, Bronder JL, et al. Breast cancer metastasis to the central nervous system. Am J Pathol 2005;167:913-920.
4. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
5. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874.
6. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010;28:3271-3277.
7. Heitz F, Harter P, Lueck HJ, et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 2009;45:2792-2798.
8. Sanna G, Franceschelli L, Rotmensz N, et al. Brain metastases in patients with advanced breast cancer. Anticancer Res 2007;27:2865-2869.
9. Curigliano G, Bagnardi V, Viale G, et al. Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol 2011;22:2227-2233.
10. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
11. Miller KD, Weathers T, Haney LG, et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 2003; 14:1072-1077.
12. Lai R, Dang CT, Malkin MG, et al. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004;101:810-816.
13. Pestalozzi BC. Brain metastases and subtypes of breast cancer. Ann Oncol 2009;20:803-805.
14. Gluz O, Liedtke C, Gottschalk N, et al. Triple-negative breast cancer-current status and future directions. Ann Oncol 2009;20:1913-1927.
15. Niwinska A, Murawska M, Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 2010;21:942-948.
16. Kamar FG, Posner JB. Brain metastases. Semin Neurol 2010;30:217-235.
17. Niwinska A, Pogoda K, Murawska M, et al. Factors influencing survival in patients with breast cancer and single or solitary brain metastasis. Eur J Surg Oncol 2011;37:635-642.
18. Rollin N, Guyotat J, Streichenberger N, et al. Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors. Neuroradiology 2006;48:150-159.
19. Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology 2009;250:638-467.
20. Jena A, Taneja S, Talwar V, et al. Magnetic resonance (MR) patterns of brain metastasis in lung cancer patients: correlation of imaging findings with symptom. J Thorac Oncol 2008;3:140-144.
21. Sekine A, Kato T, Hagiwara E, et al. Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features. Lung Cancer 2012;77:64-69.
22. Ossovskaya V, Wang Y, Budoff A, et al. Exploring molecular pathways of triple-negative breast cancer. Genes Cancer 2011;2:870-879.
23. Yonemori K, Tsuta K, Ono M, et al. Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer 2010;116:302-308.
24. Kalikaki A, Koutsopoulos A, Trypaki M, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 2008;99:923-929.
25. Wang B, Guan ZZ, Liu DG, et al. [Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer]. Ai Zheng 2004;23:1710-1713.
26. Broom RJ, Tang PA, Simmons C, et al. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 2009;29:1557-1562.
27. Metro G, Foglietta J, Russillo M, et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011;22:625-630.
28. Soffietti R, Trevisan E, Ruda R. Targeted therapy in brain metastasis. Curr Opin Oncol 2012;24:679-686.
29. Cocconi G, Lottici R, Bisagni G, et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest 1990;8:327-334.
30. Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999;85:1599-1605.